+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Epigenetic Regulation in Overcoming Chemo-Resistance, Vol 19. Cancer Sensitizing Agents for Chemotherapy

  • ID: 5137720
  • Book
  • February 2021
  • 360 Pages
  • Elsevier Science and Technology

Epigenetic Regulation in Overcoming Chemo-Resistance, Volume 19 explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored.

This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers.

  • Presents detailed diagrams of the mechanisms of epigenetic regulation for easy consult
  • Encompasses multiple clinical trial summary diagrams to help readers quickly and clearly get information from clinical trials
  • Provides future perspectives in each section to inspire readers to use epigenetic regulation to overcome chemo-resistance
Note: Product cover images may vary from those shown

1. The role of epigenetic regulation in cancer 2. DNA methyltransferase inhibitors (DNMTi) as sensitizing agents to overcome chemo-resistance 3. Histone deacetylases inhibitors (HDACi) as sensitizing agents to overcome chemo-resistance 4. Histone lysine demethylases inhibitors (HDMi) as sensitizing agents to overcome chemo-resistance 5. Histone lysine methyltransferases inhibitors (HMTi) as sensitizing agents to overcome chemo-resistance 6. Drugs regulating the microRNA to overcome chemo-resistance 7. Drugs regulating the lncRNA to overcome chemo-resistance 8. Drugs regulating the mRNA methylation to overcome chemo-resistance 9. Future combined epigenetic therapy

Note: Product cover images may vary from those shown
Wu, Chunfu
Chunfu Wu,PhD, graduated from Shenyang Pharmaceutical University in 1982 and received his PhD from Hokkaido Pharmaceutical University in 2000. In 1996, he was named Professor at Department of Pharmacology of Shenyang Pharmaceutical University. Professor Wu has presided over several major scientific research projects, including the "National High-technology Research and Development Program”, and the "National Natural Science Foundation”. Besides, he has published more than 300 articles in international peer reviewed journals. Furthermore, Professor Wu has done a lot of research in the field of cancer chemo-sensitization, especially the cancer-related epigenetic regulation.Chunfu Wu,PhD, graduated from Shenyang Pharmaceutical University in 1982 and received his PhD from Hokkaido Pharmaceutical University in 2000. In 1996, he was named Professor at Department of Pharmacology of Shenyang Pharmaceutical University. Professor Wu has presided over several major scientific research projects, including the "National High-technology Research and Development Program”, and the "National Natural Science Foundation”. Besides, he has published more than 300 articles in international peer reviewed journals. Furthermore, Professor Wu has done a lot of research in the field of cancer chemo-sensitization, especially the cancer-related epigenetic regulation.
Wang, Lihui
Lihui Wang, PhD, obtained his PhD in Pharmacology from Shenyang Pharmaceutical University in 2006. After that, Dr Wang started his investigation in the same institute, where he was promoted to full professor in 2018. From 2016 spring to 2017 summer, Dr. Wang majors in anti-cancer drug researches and went to Memorial Sloan Kettering Cancer Center in New York as a visiting investigator. Dr. Wang has published more than 20 papers, as first or corresponding author, in international peer reviewed journals, and his research focus is anti-cancer drugs development and chemo-sensitization.
Note: Product cover images may vary from those shown
Adroll
adroll